News headlines about Eyenovia (NASDAQ:EYEN) have been trending somewhat negative this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eyenovia earned a news sentiment score of -0.04 on Accern’s scale. Accern also gave press coverage about the company an impact score of 43.8525027948071 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Eyenovia (NASDAQ:EYEN) traded down $0.01 during trading hours on Wednesday, hitting $9.00. The stock had a trading volume of 9,450 shares, compared to its average volume of 28,721. Eyenovia has a 1 year low of $7.32 and a 1 year high of $10.74.
Several equities research analysts have commented on the company. Ladenburg Thalmann Financial Services assumed coverage on Eyenovia in a report on Tuesday, February 20th. They issued a “buy” rating and a $35.00 target price on the stock. Roth Capital assumed coverage on Eyenovia in a report on Tuesday, February 20th. They issued a “buy” rating and a $20.00 target price on the stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://baseballnewssource.com/2018/03/14/somewhat-negative-media-coverage-somewhat-unlikely-to-impact-eyenovia-eyen-stock-price/1926334.html.
Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.